What is the recommended dosing regimen of cotrimoxazole (trimethoprim‑sulfamethoxazole) for treating brucellosis in adults and children?

Cotrimoxazole in Brucellosis

Cotrimoxazole (trimethoprim-sulfamethoxazole) should be considered a second-line agent for brucellosis treatment, reserved primarily for children under 8 years old when combined with rifampicin, or as a third drug in triple-therapy regimens for adults with complicated disease. 1

Adult Dosing and Recommendations

For adults with uncomplicated brucellosis, cotrimoxazole is classified as a CII recommendation (poor evidence, optional use) by the Ioannina consensus guidelines 1. When used:

• Dose: TMP-SMX 800/160 mg (double-strength tablet) twice daily for 6 weeks 1
• Must be combined with other agents, preferably doxycycline
• Never use as monotherapy: A well-designed trial demonstrated a 46% relapse rate with TMP-SMX monotherapy for 45 days 1

Why Cotrimoxazole is Second-Line in Adults

The evidence clearly shows inferior outcomes compared to first-line regimens. While TMP-SMX-containing combinations achieve response rates above 90% in some studies, this is only when combined with doxycycline in triple-drug regimens 1. The Ioannina guidelines explicitly state that doxycycline combined with either streptomycin (2-3 weeks) or rifampicin (6 weeks) should be first-line (AI recommendation), with gentamicin as an acceptable alternative (BI recommendation) 1.

Critical caveat: Recent meta-analysis data from 2026 reveals significant antimicrobial resistance to cotrimoxazole, with 44.11% of isolates showing non-susceptibility 2. This resistance was particularly linked to pre-2010 studies and non-Asian continents, suggesting geographic variation in resistance patterns that must inform treatment decisions.

Pediatric Dosing and Recommendations

For children under 8 years old (where tetracyclines are contraindicated):

• Preferred regimen: Cotrimoxazole + rifampicin for 6 weeks 3, 4

  • Cotrimoxazole: 10-12 mg/kg trimethoprim + 50-60 mg/kg sulfamethoxazole in two divided doses
  • Rifampicin: 15-20 mg/kg in two divided doses

• Alternative regimen: Cotrimoxazole for 6 weeks + gentamicin for 5 days 3

Pediatric Evidence Base

A prospective trial of 113 children treated with cotrimoxazole-rifampicin for 6 weeks showed excellent results: all patients defervesced within 1-3 weeks, with only 4 relapses (3.5%) after 6 months 5. However, a 2024 systematic review found very low certainty of evidence for pediatric regimens, with summarized failure rates of 2% for cotrimoxazole-rifampicin combinations 6.

For children over 8 years: Doxycycline-based regimens are preferred, following adult protocols 3.

Special Populations

Pregnancy

Cotrimoxazole + rifampicin is the most frequently used combination in pregnant women, though evidence remains limited 7. In a systematic review of 403 pregnant women:

• Adverse obstetric outcomes occurred in 16% (95%CI: 8%-30%)
• Abortion rate: 23.3%
• Recurrence: only 3%

Dose in pregnancy: Standard adult dosing (TMP-SMX 800/160 mg twice daily) combined with rifampicin 900 mg once daily for 6 weeks 4

Renal Impairment

Dose adjustment is mandatory 8:

• CrCl >30 mL/min: Standard dosing
• CrCl 15-30 mL/min: Reduce dose by 50%
• CrCl <15 mL/min: Use not recommended

Clinical Algorithm for Cotrimoxazole Use

1. First, determine patient age and pregnancy status:

   • Adults, non-pregnant → Use doxycycline-based regimens (first-line)
   • Children <8 years → Cotrimoxazole + rifampicin (preferred)
   • Pregnant women → Cotrimoxazole + rifampicin (most common, though limited evidence)

2. If considering cotrimoxazole in adults:

   • Only use in triple-drug combinations for complicated disease
   • Never as monotherapy or dual therapy alone
   • Consider local resistance patterns (particularly important post-2010)

3. Duration: Minimum 6 weeks for all regimens containing cotrimoxazole

Common Pitfalls to Avoid

• Do not use cotrimoxazole monotherapy: This results in unacceptably high relapse rates (46%) 1
• Do not shorten duration below 6 weeks: Early studies using 3-week courses showed high relapse rates 9
• Do not ignore resistance patterns: Emerging resistance to cotrimoxazole is documented, particularly in certain geographic regions 2
• Do not use in children <2 months old: Absolute contraindication per FDA labeling 8

The evidence consistently demonstrates that while cotrimoxazole has a role in brucellosis treatment, it is inferior to tetracycline-based regimens in adults and should be reserved for specific populations where first-line agents are contraindicated.